PD173955 (PD-173955), a src-selective tyrosine kinase inhibitor, is a novel and potent Bcr-Abl inhibitor with potential anticancer activity. It inhibits Bcr-Abl with an IC50 of 1-2 nM, it also inhibits Src activity with IC50 of 22 nM.
Physicochemical Properties
Molecular Formula | C21H16CL2N4OS | |
Molecular Weight | 443.35 | |
Exact Mass | 442.042 | |
Elemental Analysis | C, 56.89; H, 3.64; Cl, 15.99; N, 12.64; O, 3.61; S, 7.23 | |
CAS # | 260415-63-2 | |
Related CAS # |
|
|
PubChem CID | 447077 | |
Appearance | white solid powder | |
Density | 1.5±0.1 g/cm3 | |
Boiling Point | 626.7±65.0 °C at 760 mmHg | |
Flash Point | 332.8±34.3 °C | |
Vapour Pressure | 0.0±1.8 mmHg at 25°C | |
Index of Refraction | 1.725 | |
LogP | 4.74 | |
Hydrogen Bond Donor Count | 1 | |
Hydrogen Bond Acceptor Count | 5 | |
Rotatable Bond Count | 4 | |
Heavy Atom Count | 29 | |
Complexity | 626 | |
Defined Atom Stereocenter Count | 0 | |
SMILES | O=C1C(C2=C(Cl)C=CC=C2Cl)=CC3=CN=C(NC4=CC=CC(SC)=C4)N=C3N1C |
|
InChi Key | VAARYSWULJUGST-UHFFFAOYSA-N | |
InChi Code | InChI=1S/C21H16Cl2N4OS/c1-27-19-12(9-15(20(27)28)18-16(22)7-4-8-17(18)23)11-24-21(26-19)25-13-5-3-6-14(10-13)29-2/h3-11H,1-2H3,(H,24,25,26) | |
Chemical Name | 6-(2,6-dichlorophenyl)-8-methyl-2-((3-(methylthio)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one | |
Synonyms |
|
|
HS Tariff Code | 2934.99.9001 | |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 1999 Dec 15;59(24):6145-52. PMID: 10626805. [2]. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia. 2005 Nov;19(11):1872-9. [3]. Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage. Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):1389-1394. [4]. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood. 2005 May 15;105(10):3995-4003. |
||
Additional Infomation | PD173955 is a dichlorobenzene, a methyl sulfide, a pyridopyrimidine and an aryl sulfide. It has a role as a tyrosine kinase inhibitor. |
Solubility Data
Solubility (In Vitro) |
|
|||
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2556 mL | 11.2778 mL | 22.5555 mL | |
5 mM | 0.4511 mL | 2.2556 mL | 4.5111 mL | |
10 mM | 0.2256 mL | 1.1278 mL | 2.2556 mL |